All the news Showing 6 of 46 articles from: Previous non-responders & relapsersGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Interferon-free hepatitis C treatment with faldaprevir proves safe and effective in people with cirrhosis Keith Alcorn / 20 November 2012 The first major data on interferon-free hepatitis C treatment in people with cirrhosis show that treatment using BI-201335 – now known as faldaprevir – and BI-207127 with ribavirin can be safe, and proved ... Simeprevir is safe and effective with interferon/ribavirin for hepatitis C patients with cirrhosis Liz Highleyman / 19 November 2012 The hepatitis C protease inhibitor simeprevir (formerly TMC435) was generally safe and well tolerated in people with advanced liver fibrosis or cirrhosis and improved sustained response rates when added to pegylated interferon and ... Sofosbuvir demonstrates high response rate in interferon-free combination with ribavirin and GS-5885 Liz Highleyman / 15 November 2012 The hepatitis C polymerase inhibitor sofosbuvir produced high rates of sustained virological response in genotype 1 patients when combined with ribavirin and the HCV NS5A inhibitor GS-5885, according to data presented this week ... Abbott Announces Phase 3 Interferon-free Hepatitis C Regimens to be Studied in Broad Patient Populations Abbott press release / 14 November 2012 Abbott interferon-free combination 'promising' in harder-to-treat patients with hepatitis C Keith Alcorn / 12 November 2012 Over 79% of previously untreated and null responder patients with genotype 1a hepatitis infection achieved a sustained virologic response twelve weeks after completing treatment (SVR12) with an interferon-free combination of two or three ... High rate of response to BMS HCV drugs in harder-to-treat patients – but interferon-free prospects differ by sub-genotype Keith Alcorn / 12 November 2012 Although an interferon-free combination of antiviral drugs developed by Bristol-Myers Squibb to treat hepatitis C was highly effective in curing the infection in previous null responders to treatment with HCV genotype 1b infection, ... ← Prev12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive